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Abstract
Human 16K PRL (16K hPRL) is a potent inhibitor of angiogenesis both in vitro and in vivo. It 
has been shown to prevent tumor growth in three xenograft mouse models. Here we have used 
a gene transfer method based on cationic liposomes to produce 16K hPRL and demonstrate 
that 16K hPRL inhibits tumor growth in a subcutaneous B16F10 mouse melanoma model. 
Computer-assisted image analysis shows that 16K hPRL treatment results in the reduction of 
tumor vessel length and width, leading to a 57% reduction in average vessel size. We thus 
show, for the first time, that administration of the 16K hPRL gene complexed to cationic 
liposomes is effective to maintain antiangiogenic activities of 16K hPRL level. 
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1. Introduction
Angiogenesis, the formation of new blood vessels from pre-existing ones, is essential to organ 
growth and repair. An imbalance in this process contributes to the pathogenesis of numerous 
disorders, notably cancer[1]. Angiogenesis is a multi-step process including endothelial cell 
proliferation, migration, basement membrane degradation, and new lumen organization. 
Within a given microenvironment, the angiogenic response is regulated by a balance between 
pro- and anti-angiogenic regulators[2]. Induction of a tumor vasculature, termed the 
“angiogenic switch”, occurs when this balance tips in favor of pro-angiogenic factors[3]. The 
role of angiogenesis in tumor growth and progression being firmly established, considerable 
efforts have focused on antiangiogenic therapy as a new form of cancer treatment[2], 
especially since angiogenesis inhibitors have two advantages: they are less toxic than 
conventional chemotherapy and entail a lower risk of drug resistance[4]. Antiangiogenic 
therapy is now considered as an effective approach for cancer therapy, indeed FDA-approved 
antiangiogenic therapies in oncology.
There are currently eight approved anti-cancer therapies with recognized antiangiogenic 
properties. These agents, which interrupt critical cell signaling pathways involved in tumor 
angiogenesis and growth, comprise two primary categories: 1) monoclonal antibodies directed 
against specific proangiogenic growth factors and/or their receptors (examples: Avastin®, 
Herceptin®); and 2) small molecule tyrosine kinase inhibitors (TKIs) of multiple 
proangiogenic growth factor receptors (examples: Tarveca®, Nexavar®). Inhibitors of mTOR
(mammalian target of rapamycin) represent a third, smaller category of antiangiogenic 
therapies with one currently approved agent. In addition, at least two other approved 
angiogenic agents may indirectly inhibit angiogenesis through mechanisms that are not 
completely understood.
16K PRL, the 16-kDa N-terminal fragment of prolactin, is a potent negative regulator of
angiogenesis. We have previously shown that it is antiangiogenic both in vitro and in vivo[5-
12]. Very recently, human 16K PRL (16K hPRL) was shown to play a role in postpartum 
cardiomyopathy[13]. Its antitumor activity has been demonstrated in three mouse models. 
Bentzien and collaborators have shown that 16K hPRL, produced by human HCT116 colon 
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cancer cells, markedly reduces their ability to form subcutaneous (s.c.) tumors in Rag1-/-
mice[14]. Moreover, by using an adenovirus vector as gene transfer method for 16K hPRL, 
Kim and collaborators and also Nguyen and collaborators, have respectively shown that the 
expression of 16K hPRL in prostate cancer cells leads to tumor growth inhibition and that 
16K hPRL inhibits tumor growth in a s.c. B16F10 mouse melanoma model and reduces the 
establishment of B16F10 metastasis in an experimental lung metastasis model[15,16].
There are obstacles to carrying out clinical trials of antiangiogenic protein therapy: prolonged 
protein therapy, repeated administration, high dosages, toxicity risks, and high cost. To 
overcome these problems, it is thus necessary to develop alternative strategies. 
Antiangiogenic gene therapy has become one of the most attractive approaches to the 
treatment of cancer[17]. In particular, non-viral delivery of the payload gene via “lipoplexes” 
(complexes of cationic liposomes and plasmid DNA) has become popular in both in vitro and 
in vivo research in this field. Liposomal vectors offer clear advantages over recombinant viral 
vectors: they are non-pathogenic and less immunogenic; they impose no limit on transgene 
size and are simple to prepare and use. Cationic liposomes appear particularly suitable for 
antiangiogenic antitumor therapy, as Thurston and his collaborators have shown in a mouse 
system that they target mainly tumoral blood vessels[18]. Maeda and collaborators have also 
shown that liposomes tend to accumulate in tumor tissues through the angiogenic endothelium 
via the enhanced permeability and retention effect[19]. For these reasons, cationic liposomes 
have been used as safe vehicles for gene transfer in a variety of gene therapy clinical trials, 
and notably in antiangiogenic gene therapy[20-22].
In this study we have investigated the effect of 16K hPRL on primary tumor development 
from B16F10 murine melanoma cells. We provide evidence that 16K hPRL, administered by 
cationic-liposome-mediated gene transfer, can reduce tumor growth by altering the vascular 
morphology of tumors.
2. Materials and Methods
2.1. Cell lines, animals, and reagents
Transformed human kidney cells (293T cells) were cultured in DMEM 1000 (50%) and HAM 
F12 (50%) supplemented with 10% FBS and antibiotics (100 units/ml penicillin and 
100µg/ml streptomycin) at 37 °C in a humid atmosphere containing 5% CO2. B16F10 mouse 
melanoma cells were obtained from the American Type Culture Collection (ATCC CRL-
6475, Rockville, Md) and cultured in DMEM 4500 supplemented with 10% FBS and 100 
units/ml penicillin, 100µg/ml streptomycin at 37 °C in a humid atmosphere containing 5% 
CO2. All culture reagents were purchased from Invitrogen Corp./Life Technologies (CA,
USA). Adult female C57BL/6J mice (6-8 weeks of age) purchased from the Central Animal 
Facility of CHU Liège (Liège, Belgium) were used to assess tumor growth.
DOTAP (1,2-Dioleoyl-3-trimethylamonium propane) and cholesterol were purchased from 
Avanti Polar Lipids, Inc (Alabaster, AL, USA). Lipofectamine reagent was purchased from 
Invitrogen Corp./Life Technologies (CA, USA).
2.2. DNA preparation
Plasmids pcDNA3.1–16K hPRL and pcDNA3.1 were amplified and purified with the 
EndoFree Plasmid Megaprep Kit (QIAGEN, Hilden, Germany). This kit makes it possible to 
remove endotoxin.
2.3. Cationic liposome synthesis
DOTAP and cholesterol (1:1 w/w) were mixed and dissolved in chloroform/methanol (1:1 
v/v). The solution was evaporated under vacuum in a rotary evaporator until a thin lipid film 
was formed. The lipids were kept under vacuum overnight to ensure removal of the residual 
organic solvent. The following day, the dried lipid film was hydrated with 2 ml phosphate-
buffered saline (PBS) to form multilamellar liposomes. The suspension was left for 2 hours to 
allow swelling of the liposomes. 5 cycles of freezing under N2/thawing at 37 °C were 
performed to weaken the membrane lipids. Finally, an extruder (Polar Lipids, Inc. Alabaster, 
AL, USA) was used to extrude the suspension 10 times through polycarbonate filters (pore 
size: 100 nm). The liposomes were stored at 4 °C.
2.4. Preparation of DNA:liposome complexes (lipoplexes) 
For in vitro gene transfection, 100 (or 50) µg liposomes (or lipofectamine) were diluted in 250 
µl Optimem, and 10 (or 5) µg plasmid DNA was also diluted in 250 µl Optimem. The 
resulting mixtures were mixed and incubated at room temperature for 30 minutes to form 
stable DNA:liposome complexes. For in vivo transfection, an equal volume of plasmid DNA 
solution was added to the liposome solution by slow dropwise addition with continuous 
mixing to achieve a 1:10 DNA:lipid ratio (by weight). The resulting lipoplexes were 
incubated at room temperature for 30 minutes before administration to mice.
2.5. Western blot analysis
37.5 µl from conditioned medium of 293T cells transfected with lipoplexes containing 
cationic liposomes (100 µg) and pcDNA3.1 or pcDNA3.1-16K hPRL (10 µg) was resolved by 
SDS-PAGE and transferred to a polyvinylidene fluoride membrane (Millipore Corp., Bedford, 
MA, USA). Membranes were saturated for 1 hour in TBS-8% dry milk, followed by 
incubation for 1 hour with a 1/500 dilution of anti-16K hPRL antibody (A602) and for 1 hour 
with a 1/5000 dilution of peroxidase-conjugated goat antirabbit antibody (Gamma, 
BioWhittaker, Verviers, Belgium). 16K hPRL detection was done by chemiluminescence with 
the ECL Plus Kit (Amersham Biosciences, Arlington Heights, IL, USA). For the 
deglycosylation experiments, the N-Glycosidase F Deglycosyltion Kit was used according to 
the manufacturer’s instructions (Roche, Palo Alto, CA) as previously described[23]. 
2.6. qRT-PCR
Total RNA was extracted from 30 mg tumor tissue with MagNA Lyser Green Beads 
according to the manufacturer’s instructions (Roche Applied Science, Mannheim, Germany). 
RNA was isolated with the Qiagen Rneasy Mini kit (Qiagen, Hilden, Germany) and treated 
with Dnase (RQ1 RNase-Free Dnase, Promega, Madison, WI). cDNA was synthesized from 1 
µg total RNA by reverse transcription with the RT Transcriptor First Strand cDNA Synthesis 
Kit (Roche Clinical Laboratories, Indianapolis, IN) according to the manufacturer’s 
instructions. The resulting cDNA (300 pg) was used for real-time PCR with the one-step 2x
Mastermix (Diagenode, Liège, Belgium) containing SYBR green. Thermal cycling was 
performed on an Applied Biosystems 7000 detection system (Applied Biosystems, Foster 
City, CA). For all reactions, negative controls were run with no template present, and random 
RNA preparations were also subjected to sham qRT-PCR (no reverse transcription) to verify 
lack of genomic DNA amplification. The relative transcript levels for the genes of interest 
were obtained by the relative standard curve method and normalized with respect to the 
housekeeping gene cyclophilin B. Primers, the sequences of which are available upon request,
were designed with the Primer Express 2.0 software (Apply Biosystem, Forster City, USA) 
and selected so as to span exon-exon junctions, to avoid detection of genomic DNA. 
2.7. In vitro transfection 
293T cells were seeded into 10-cm plates at a density of 4.5 x 106 cells per plate. 24 hours 
later, the medium was replaced with serum-free medium and then prepared lipoplexes were 
added to the culture plates (10 µg DNA per plate), which were then incubated at 37 °C in 5% 
CO2 for 4 hours. The transfected cells were incubated for another 48 hours in the presence of 
serum-containing medium.
2.8. In vivo gene transfection
Subconfluent B16F10 were trypsinized, washed, and resuspended in PBS. Cell suspension 
(105 cells in 50 µl) was injected s.c. into the right flanks of C57BL/6J mice. Experimental 
groups of twelve mice were used and randomly divided. Three days later, prepared lipoplexes 
(50 µg plasmid DNA/500 µg cationic liposomes) were inoculated s.c. into the peritumoral 
region. This injection was repeated every three or four days. Eighteen days after cell injection, 
the mice were sacrificed and tumors harvested. Tumor growth was assessed by measuring the 
length and width of each tumor every one or two days and calculating its volume by means of 
the formula: length x width2 x 0.5. Results are expressed as the mean tumor volume for each 
experimental group. 
2.9. Histology and immunohistochemistry
Tumors were embedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, The Netherlands) and 
frozen at –70 °C prior to sectioning (into slices 5 µm thick). To study overall tissue 
morphology, frozen sections were stained with hematoxylin/eosin. For assessment of 
angiogenesis, tumor vessels were stained with CD31. For CD31 staining, frozen sections were 
fixed in 80% MetOH (VWR, Leuven, Belgium) for 10 minutes at -20 °C. Endogenous 
peroxidase was subsequently blocked with 3% H2O2/H20 (Sigma-Aldrich, Steinheim, 
Germany) for 20 minutes, and non-specific binding was prevented by incubation in normal 
rabbit serum for 1 hour at room temperature. Sections were then incubated first with a rat 
monoclonal anti-CD31 (1/250, BD Biosciences, Erembodegem, Belgium) for 1 hour at room 
temperature, then with a biotinylated secondary antibody (1/400, DAKO, Heverlee, Belgium) 
for 30 minutes at room temperature. This was followed by incubation with streptavidin/HRP 
complex (1/500, DAKO, Heverlee, Belgium). CD31-positive cells were visualized after 
sections were colored for 3 minutes with 3-amino-9- ethylcarbazole (DAKO, Heverlee, 
Belgium). Sections were finally counterstained with hematoxylin and mounted for 
microscopy with Aqua Polymount (Polysciences Inc., Warrington, PA, USA).
2.10. Image processing and measurements
Images were digitized in 1360 x 1024 pixels in the red-green-blue (RGB) color space. Image 
processing and measurements were performed with the software Aphelion 3.2 from Adsis 
(France) on a PC as described previously[16]. Briefly, 15 images, including a total of about 
500 vessels, were analyzed for each condition. Immunostaining of histological tumor sections 
for CD31 makes it possible to distinguish tumor vessels from tissue. The red component of 
the RGB color image corresponding to vessels was first extracted and the resulting image was 
further processed. The following measurements were performed:
(a) Vessel density defined as the number of vessels per unit of tissue area
(b) Area density defined as the percentage of tissue area occupied by vessels
(c) Vessel size distribution.
2.11. Statistical analysis
All data are expressed as means ± SME. Analyses for statistical significance (the Mann-
Whitney test) were carried out with Prism 4.0 software (GraphPad Software, San Diego, CA, 
USA). Statistical significance was set at P < 0.05.
3. Results
3.1. Transfection with cationic liposomes composed of DOTAP and cholesterol
To check whether cationic liposomes composed of DOTAP and cholesterol allow efficient 
transfection in vitro, we used them to transfect 293T cells, a cell line known to be efficiently 
transfectable by liposomes. The cells were treated with lipoplexes consisting of cationic 
liposomes and pCMTEGFP (a plasmid allowing eGFP expression). For comparison, 
transfection with lipofectamine and pCMTEGFP was also included. 24 hours after treatment, 
the cells were analyzed by fluorescence microscopy. The results show that cationic liposomes 
are very efficient transfer gene vectors. The comparison with lipofectamine points out that 
cationic liposomes are as efficient as even more lipofectamine (Fig 1).
3.2. Cationic liposomes allow expression of 16K hPRL in vitro
The ability of cationic liposomes to allow 16K hPRL expression was assessed in vitro with 
the 16K hPRL-encoding plasmid pcDNA3.1-16K hPRL. 293T cells were treated with 
lipoplexes composed of cationic liposomes (50 µg) and pcDNA3.1-16K hPRL or pcDNA3.1 
(5 µg). After 48 hours of transfection, the culture medium was collected and assayed by 
immunoblotting. Immunostaining with anti-16K hPRL antibody revealed 16K hPRL 
expression (Fig 2a). Western blot analysis revealed a band running higher than that seen for 
recombinant 16K hPRL produced in Escherichia coli (Fig 2a). This is due to the N-
glycosylation of Asn 31 of 16K hPRL. Deglycosylation of the cell culture medium with N-
glycosidase F revealed a band co-migrating with the recombinant 16K hPRL made in E. coli
(Fig 2b), as previously shown[23].
3.3. 16K hPRL expression by cationic liposomes inhibits tumor growth in a mouse 
model
The effect of 16K hPRL on solid tumor growth was assessed in a mouse model of B16F10 
melanoma. 105 B16F10 cells were subcutaneously injected into C57BL/6J mice. Two groups 
of twelve mice were used. One group was treated peritumorally every three to four days with 
lipoplexes consisting of cationic liposomes (500 µg) and plasmid pcDNA3.1-hPRL 16K (50 
µg) and the other group was treated similarly with lipoplexes consisting of cationic liposomes 
(500 µg) and control plasmid pcDNA3.1 (50 µg). Tumors grown in 16K hPRL-treated mice 
displayed a volume significantly smaller than the tumors of the control group (Fig 3). We 
monitored the effect of 16K hPRL on tumor growth in two independent experiments. In both 
experiments, tumor growth was reduced in the mouse groups treated with 16K hPRL. 
3.4 The 16K hPRL gene is expressed in B16F10 tumors
The 16K hPRL mRNA level was assessed in mouse tumors treated with plasmid pcDNA3.1-
16K hPRL or pcDNA3.1 by quantitative RT-PCR performed on cDNA samples prepared by 
reverse transcription from mouse-tumor RNA extracts. Figure 4 shows that 16K hPRL mRNA 
was detected at a high level in tumors from mice treated with plasmid pcDNA3.1- 16K hPRL. 
3.5 Modification of vascular morphology by 16K hPRL
Considering the previously described ability of 16K hPRL to alter tumoral vasculature[16], 
we used anti-CD31 antibodies to immunostain tumor blood vessels in sections obtained from 
both groups of mice. We observed interesting differences in tumor-vessel morphology and 
size between the two groups, the blood vessels appearing smaller and collapsed in tumors 
treated with 16K hPRL (Fig 5a). Computer-assisted image analysis was used to quantify 
vessel density (number of CD31-positive vessels per µm² tumor area), vessel area density 
(percentage of the tumor area occupied by blood vessels), and vessel size distribution (Fig 5b-
e). Although the average vessel density was similar in the two groups (Fig 5b), the vessel area 
density was smaller in the 16K hPRL-treated mice (Fig 5c). This was due to the smaller 
length and width of blood vessels in the 16K hPRL-treated tumors than in the control tumors, 
resulting in a 57% reduction in blood vessel size (Fig 5d). Accordingly, the vessel size 
distribution histogram (Fig 5e) shows a reduction in the number of vessels above 2000 µm² in 
size after treatment with 16K hPRL. These results confirm that the antiangiogenic factor 16K 
hPRL can reduce the development of B16F10 melanoma by altering tumor vasculature.
4. Discussion
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a phenomenon 
intervening in several physiological and pathological processes[1]. In 1971, Dr. Judah 
Folkman first proposed that tumor growth is angiogenesis-dependent[24]. Activation of 
tumoral angiogenesis is due to an imbalance between pro- and anti-angiogenic factors. Bouck 
and his collaborators have thus proposed the “angiogenic switch” model to explain tipping of 
the balance in favor of pro-angiogenic factors[25]. Angiogenesis has thus become a 
therapeutic target of great interest in cancer research.  
Among antiangiogenic factors, 16K hPRL appears as an interesting candidate. The 
antitumoral effect of 16K hPRL has already been evaluated in three murine models[14,16,21]. 
In these studies, 16K hPRL was produced either by injected tumor cells transformed 
beforehand in vitro with an appropriate expression vector or from an adenoviral vector 
injected at the site of nascent tumors. Here, we have evaluated the antitumor effect of 16K 
hPRL in a murine system after non-viral transfer of the 16K hPRL-encoding gene. For this we 
have used cationic liposomes to induce the expression of 16K hPRL in the environment of 
B16F10 melanoma tumoral cells established subcutaneously in the right flanks of C57BL/6J 
mice. We chose to use B16F10 cells because they are highly invasive, and four major reasons 
justified our choice of cationic liposomes as gene carriers. Firstly, cationic liposomes are non-
immunogenic, unlike viral vectors. Secondly, they can be produced easily and in large 
quantity. Thirdly, their positive charges interact electrostatically with the negative charges of 
DNA and they preferentially target tumoral blood vessels. Lastly, many experiments have 
proven the efficiency of cationic liposomes as gene transfer vehicles[20,21,26,27]. Here we 
have demonstrated this efficiency in vitro with the plasmid allowing expression of eGFP.
On the basis of tumor volumes measured in mice treated with pcDNA3.1- 16K hPRL or 
pcDNA3.1, we clearly show that 16K hPRL administered in this way can reduce tumor 
growth. These results validate both cationic liposomes as efficient gene vehicles in vivo and 
the use of the antiangiogenic factor 16K hPRL as an antitumor agent in our mouse model. 
Furthermore, in keeping with the observation of Nguyen and her collaborators that the 
antitumor activity of 16K hPRL in a subcutaneous tumor model is associated with an effect on 
tumor blood vessel morphology[16], our CD31 immunostaining data show that the tumor 
vessels are smaller and more collapsed following 16K hPRL treatment. This observation is 
corroborated by computer-assisted image analysis revealing a 57% decrease in the average 
vessel area in pcDNA3.1- 16K hPRL-treated than in pcDNA3.1-treated tumors. As suggested 
by Nguyen, 16K hPRL could be having an effect on vascular tone. Indeed 16K hPRL is 
known to inhibit eNOS activation by blocking intracellular Ca2+ mobilization, and this action 
results in inhibition of both angiogenesis and vasorelaxation[28].
In conclusion, this study again underlines the ability of 16K hPRL to inhibit tumor growth 
efficiently in a mouse model, this inhibition being mediated by an effect of 16K hPRL on 
tumor blood vessel morphology. Our results also highlight liposome-mediated gene therapy as 
a promising alternative to protein therapy.
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Titles and legends to figures
Figure 1 Comparison of transfection efficiencies of cationic lipoplexes and lipofectamine in 
293T cells. For both transfection vehicles the same amount of DNA (pCMTEGFP = 10 µg) 
was used. Cationic liposomes (equivalent to 100 µg lipid) were composed of a 
DOTAP/cholesterol mixture at a molar ratio 1:1. Lipofectamine (equivalent to 100 µg lipid) 
was used as instructed by the manufacturer. Analyses were performed under a fluorescence 
microscope (x100 magnification).
Figure 2 Cationic liposomes allow in vitro expression of 16K hPRL. (a) Transfection of 293T 
cells with a plasmid encoding 16K hPRL was carried out in 100-mm plates with the help of 
DOTAP/cholesterol cationic liposomes. After 48h of incubation, the cell culture media were 
subjected to SDS-PAGE and then analysed by western blotting with an anti-16K hPRL 
antibody. Lane 1; 30 ng recombinant 16K hPRL produced in Escherichia coli (loaded as a 
control), lane 2; proteins from the culture medium of cells transfected with the empty plasmid 
(pcDNA3.1) lane 3; proteins from the culture medium of cells transfected with the plasmid 
containing the 16K hPRL gene (pcDNA3.1-16K hPRL). The band corresponding to 16K 
hPRL is indicated. (b) Analysis of glycosylation. Lane 4; 30 ng recombinant 16K hPRL 
produced in Escherichia coli (loaded as a control), lane 5; proteins from the culture medium 
of cells transfected with plasmid pcDNA3.1-16K hPRL; lane 6; deglycosylated proteins from 
the culture medium of cells transfected with plasmid pcDNA3.1-16K hPRL. Culture medium 
of pcDNA3.1-16K hPRL-liposome-transfected 293T cells was incubated or not with N-
glycosidase and subjected to western blotting as in a. The band corresponding to 16K hPRL is 
indicated.
Figure 3 Reduction of B16-F10 melanoma growth by 16K hPRL. (a) C57BL/6J mice were 
subcutaneously inoculated with 105 B16F10 cells. After 3 days, the mice were treated with 
either pcDNA3.1-liposome complexes or pcDNA3.1-16K hPRL-liposome complexes. The 
complexes were injected peritumorally every 3 to 4 days. Each point represents the mean 
tumor volume in a group of mice. Error bars represent standard deviations. (b) Tumor 
volumes in mice at the end of the assay. Horizontal lines indicate the median tumor volume.
Figure 4 Measurement of the level of 16K hPRL mRNA in B16F10 tumors by qRT PCR. 
RNA was extracted from tumors treated with lipoplexes composed of cationic liposomes and 
pcDNA3.1 or pcDNA3.1-16K hPRL. Transcript levels were analyzed by qRT-PCR. Data 
were normalized by quantification of cyclophilin B transcripts and are representative of three 
distinct experiments. Each bar represents the mean ± SD, n=3.
Figure 5 16K hPRL reduces the vessel area in tumors. (a) Representative photographs of 
sections of tumors treated with pcDNA3.1-liposome complexes or with pcDNA3.1-16K 
hPRL-liposome complexes by inoculation into mice. The sections are stained with anti-CD31 
to reveal blood vessels (red) (x100 magnification). (b) The mean vessel density ± SEM was 
determined on CD31-positive vessels in x100 power fields of each section as described under 
Materials and Methods. (c) Total vessel area ± SEM was determined on CD31-positive 
vessels in x100 power fields of each section as described under Materials and Methods. (d) 
The average vessels size ± SEM was determined on CD31-positive vessels in x100 power 
fields of each section as described under Materials and Methods. (e) The size distribution ± 
SEM was determined on CD31-positive vessels in x100 power fields of each section as 
described under Materials and Methods.
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